ProfileGDS5678 / 1423217_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 90% 90% 92% 91% 91% 88% 90% 90% 89% 89% 90% 90% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.0421689
GSM967853U87-EV human glioblastoma xenograft - Control 27.23690
GSM967854U87-EV human glioblastoma xenograft - Control 37.3334190
GSM967855U87-EV human glioblastoma xenograft - Control 47.7203192
GSM967856U87-EV human glioblastoma xenograft - Control 57.3994191
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1413991
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6760588
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1253690
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2619690
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1040789
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9113189
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.3014590
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.1670790
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3608891